肺筛查报告与数据系统(Lung-RADS)替代诊断随访间隔对肺癌筛查效果的评价
本研究利用肺癌结局模拟器评估Lung-RADS 3类和4A类结节替代诊断随访间隔的人群效果。结果显示4A类推荐3个月随访间隔为最优;而3类结节采用5个月而非推荐的6个月随访间隔可带来更高的死亡率下降和更多避免的死亡,每百万一般人群合并低剂量CT与诊断随访次数更低。对结节进展阈值的敏感性分析验证了3类结节提前1个月随访可带来更高死亡率下降。
要点
- Lung-RADS 4A类结节推荐3个月随访间隔为最优。
- Lung-RADS 3类结节5个月随访可能优于推荐的6个月。
- 3类结节提前1个月随访值得进一步研究。
核心结论
- Lung-RADS 4A类推荐3个月随访间隔为最优。
- Lung-RADS 3类结节采用5个月而非推荐的6个月随访间隔可带来更高死亡率下降和更多避免的死亡。
- 对结节进展阈值的敏感性分析验证了3类结节提前1个月随访可带来更高死亡率下降。
研究设计与样本
- 研究采用肺癌结局模拟器(Lung Cancer Outcome Simulator)进行微模拟建模分析。
- 该模拟器是在癌症干预与监测建模网络联盟内开发,用于评估国家筛查指南结局。
诊断标准与关键数值
- Lung-RADS 4A类推荐3个月随访间隔为最优。
- Lung-RADS 3类结节5个月随访间隔较6个月随访间隔死亡率下降更高(男性0.08% vs 女性0.05%)。
- Lung-RADS 3类结节5个月随访间隔较6个月随访间隔避免死亡数更高(36 vs 27)。
- Lung-RADS 3类结节5个月随访间隔较6个月随访间隔筛查检出病例数更高(13 vs 7)。
- Lung-RADS 3类结节5个月随访间隔较6个月随访间隔每避免一例死亡合并低剂量CT与诊断随访次数更低(8 vs 5),每百万一般人群。
临床应用与阅片要点
- 对于Lung-RADS 3类结节,可考虑将随访间隔从推荐的6个月缩短至5个月以可能提高筛查效果。
- 对于Lung-RADS 4A类结节,维持推荐的3个月随访间隔。
局限性
- 研究基于模拟模型估计,非真实人群直接验证。
- 原文未报告模拟模型的具体参数设置和验证细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The ACR developed the Lung CT Screening Reporting and Data System (Lung-RADS) to standardize the diagnostic follow-up of suspicious screening findings. A retrospective analysis showed that Lung-RADS would have reduced the false-positive rate in the National Lung Screening Trial, but the optimal timing of follow-up examinations has not been established. In this study, we assess the effectiveness of alternative diagnostic follow-up intervals on lung cancer screening.
METHODS: We used the Lung Cancer Outcome Simulator to estimate population-level outcomes of alternative diagnostic follow-up intervals for Lung-RADS categories 3 and 4A. The Lung Cancer Outcome Simulator is a microsimulation model developed within the Cancer Intervention and Surveillance Modeling Network Consortium to evaluate outcomes of national screening guidelines. Here, among the evaluated outcomes are percentage of mortality reduction, screens performed, lung cancer deaths averted, screen-detected cases, and average number of screens and follow-ups per death averted.
RESULTS: The recommended 3-month follow-up interval for Lung-RADS category 4A is optimal. However, for Lung-RADS category 3, a 5-month, instead of the recommended 6-month, follow-up interval yielded a higher mortality reduction (0.08% for men versus 0.05% for women), and a higher number of deaths averted (36 versus 27), a higher number of screen-detected cases (13 versus 7), and a lower number of combined low-dose CTs and diagnostic follow-ups per death avoided (8 versus 5), per one million general population. Sensitivity analysis of nodule progression threshold verifies a higher mortality reduction with a 1-month earlier follow-up for Lung-RADS 3.
CONCLUSIONS: One-month earlier diagnostic follow-ups for individuals with Lung-RADS category 3 nodules may result in a higher mortality reduction and warrants further investigation.
引用
- Bastani M, Toumazis I, Hedou' J, et al. Evaluation of Alternative Diagnostic Follow-up Intervals for Lung Reporting and Data System Criteria on the Effectiveness of Lung Cancer Screening. J Am Coll Radiol. 2021. PMID: 34419477. doi:10.1016/j.jacr.2021.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。